Circular economy
Boehringer Ingelheim strives to use resources for as long as possible, process them for reuse or recycle them.
Search
Be green Japan
Boehringer Ingelheim's Yamagata site is gradually switching to a more sustainable energy supply.
Our Partners_ViraTherapeutics
Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
Obesity osteoarthritis in pets a blind spot
Same as with humans, body weight is just one indicator among many when it comes to a pet’s health status. However, there are some diseases associated with it. Learn more here.
Protein Degraders in Cancer
Boehringer Ingelheim scientists and their partners are exploring how protein degraders could bring so-called undruggable cancer targets within reach
Stargardt Disease
Stargardt Disease is a hereditary condition causing and progressive vision loss, typically during childhood or adolescence.
Understanding heart failure
Heart failure is a complicated clinical condition which affects more than 60 million people worldwide. Find out more about the condition here.
COVID-19 Ivermectin Animal Health Not for Human Use
Boehringer Ingelheim manufactures several veterinary products containing ivermectin. They are not approved or suitable for use in humans to try to prevent or treat COVID-19.
SIRPα Cancer Immunology Research
Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
Bridging the gap in Generalized Pustular Psoriasis (GPP)
Emmanuelle Clerisme-Beaty, Head of Clinical Development and Medical Affairs, Dermatology, discusses recently published insights from GPP patients.
Advancing regenerative medicine
Strategic partnerships play a key role in helping the company accelerate the next generation of breakthroughs.
Bees and biodiversity
At Boehringer Ingelheim we attach great importance to sustainable planting on our company site – and to protecting the bees.
Waste
Resource conservation at Boehringer Ingelheim is managed as part of an ongoing process of prevention and reduction of material usage and waste.
History of the logo
Overview of the history of the corporate logo of Boehringer Ingelheim, from the founding years of the company until today
EHS management approach
We protect our employees, facilities and the environment from harmful influences, conserve natural resources and promote environmental awareness
Patient Organizations
Boehringer Ingelheim’s core principles and vision guide our work with patient organisations.
New approaches in the battle against heartworm disease
Heartworm disease is a concern to dog and cat owners worldwide. Current disease control methods are increasingly challenged by drug resistance. We explore the potential for novel treatments and vaccines based on new knowledge and technology.
A beginner’s guide to fighting off cat parasites
Prof. Donato Traversa explains the risk of multiparasitic infections and/or infestations in cats
FuturePack
Boehringer Ingelheim has built a new special machine that enables efficient and sustainable packaging of small batches.
Complications of Diabetic Retinopathy
Both Diabetic Macular Edema and Ischemia are maculopathies, they specifically affect the macula, responsible for high visual acuity.
Industry 40 Innovation in France
Our sites in the Lyon area and Toulouse are investing in the industry of the future.
Research in Diabetic Macular Ischemia
There are no available treatments for DMI. Scientists at Boehringer Ingelheim are working hard to change this.
Different life stages dogs preventive health
What does your dog need to thrive at every age? Get some tips here!
Fighting against rabies through vaccination and education
Dr. Silvina Muñiz is sharing her insights about rabies prevention and explains why education is essential.
One step further in fighting rabies in Vietnam
A expedition team set off to the Duc Hue District. The purpose? To vaccinate the entire dog and cat population of several villages.